This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants w…

Anaplastic Thyroid CancerThyroid CancerBRAF Mutation-Related Tumors

~Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT06902376

Phase 2

A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial

The goal of the trial is to improve this OS by 4 months (to 9.9 months) using the zanzalintinib + cemiplimab treatment combination. Given an accrual period of …

Anaplastic Thyroid Cancer

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07470489